Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies


Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI Tech Co., Ltd., Complete Genomics Inc., BGI Americas Corp., and MGI Americas Inc. The preliminary injunction was granted in two patent infringement lawsuits that Illumina filed against BGI in June 2019 (Case No. 3:19-cv-03770) and February 2020 (Case No. 3:20-cv-01465).

The preliminary injunction order prohibits BGI from launching its sequencing instruments and related reagents in the United States. The order prohibits the supply, use or sale of both the standard and “CoolMPS” chemistries.

“We are pleased with the Court’s decision. It validates that BGI has blatantly copied Illumina’s proprietary sequencing chemistry,” said Charles Dadswell, SVP and General Counsel for Illumina. “Illumina’s patents reflect the hard work, dedication and investment made by Illumina and its scientists, revolutionizing the industry and dramatically driving down the cost of sequencing.”

The preliminary injunction is based on U.S. Patent Nos. 7,541,444; 7,566,537; 7,771,973; 9,410,200; and 10,480,025. The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry. Related patent suits are pending in Denmark, Finland, Germany, Sweden, Switzerland, Turkey, and the UK. The trial in the US case is scheduled to begin on May 25, 2021.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005978/en/

Illumina Inc. Aktie

117,38 €
5,58 %
Die Illumina Inc. Aktie verzeichnet heute einen großen Anstieg um 5,58 %.
Hohe Buy- und niedrige Sell-Zahlen bei Illumina Inc. zeigen ein stark positives Sentiment.
Die Community erwartet für Illumina Inc. ein Kursziel von 163 €, was eine Steigerung von über 20% gegenüber 117.38 € bedeuten würde.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare